Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the Application:

1-92. (Canceled)

93. (New) A vesicular composition, comprising:

(a) a vesicle consisting essentially of one or more phosphatidyl cholines and one or more amphiphilic non-steroidal anti-inflammatory drug surfactants; and

(b) an aqueous medium.

94. (New) The composition of claim 93, wherein the aqueous medium is a buffer.

95. (New) The composition of claim 94, wherein the buffer has a pH of 3 to 12.

96. (New) The composition of claim 94, wherein the buffer has a pH of 5 to 9.

97. (New) The composition of claim 94, wherein the buffer has a pH of 6 to 8.

98. (New) The composition of claim 93, wherein at least one of the one or more phosphatidyl cholines is a natural phosphatidylcholine.

99. (New) The composition of claim 98, wherein at least one of the one or more phosphatidyl cholines is from egg, soybean, coconut, olive, saffron, sunflower, linseed, whale fat, primrose, or primula.

100. (New) The composition of claim 93, wherein at least one of the one or more phosphatidyl cholines is a synthetic phosphatidyl choline.

101. (New) The composition of claim 93, wherein at least one of the one or more non-steroidal anti-inflammatory drugs is diclofenac or ibuprofen.

102. (New) The composition of claim 93, further comprising a consistency modifier, an antioxidant, or a stabilizer.

103. (New) The composition of claim 102, wherein the consistency modifier is a hydrogel.

104. (New) The composition of claim 102, wherein the antioxidant is probucol, tocopherol, BHT, ascorbic acid, or desferroxamine.

105. (New) The composition of claim 102, wherein the stabilizer is phenol, cresol, or benzyl alcohol.

106. (New) A method for transporting a non-steroidal anti-inflammatory drug through human or animal skin or mucous membranes, comprising administering the composition of claim 93 to the human or animal.

107. (New) The composition of claim 106, wherein the aqueous medium is a buffer.

108. (New) The composition of claim 107, wherein the buffer has a pH of 3 to 12.

109. (New) The composition of claim 108, wherein the buffer has a pH of 5 to 9.

110. (New) The composition of claim 109, wherein the buffer has a pH of 6 to 8.

111. (New) The method of claim 106, wherein the composition is administered percutaneously, orally, or parenterally.

112. (New) The method of claim 106, wherein at least one of the one or more phosphatidyl cholines is a natural phosphatidyl choline.

113. (New) The method of claim 112, wherein at least one of the one or more phosphatidyl cholines is from egg, soybean, coconut, olive, saffron, sunflower, linseed, whale fat, primrose, or primula.

114. (New) The method of claim 106, wherein at least one of the one or more phosphatidyl cholines is a synthetic phosphatidyl choline.

115. (New) The method of claim 106, wherein at least one of the one or more non-steroidal anti-inflammatory drugs is diclofenac or ibuprofen.

116. (New) The method of claim 106, wherein the composition further comprises a consistency modifier, an antioxidant, or a stabilizer.

117. (New) The method of claim 116, wherein the consistency modifier is a hydrogel.

118. (New) The method of claim 116, wherein the antioxidant is probucol, tocopherol, BHT, ascorbic acid, or desferroxamine.

119. (New) The method of claim 116, wherein the stabilizer is phenol, cresol, or benzyl alcohol.

120. (New) The method of claim 106, wherein up to 50 mg of the vesicle are administered per cm^2 of skin surface.